Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week open-label Phase IIIb study of Seroquel in children and adolescents with bipolar I disorder or schizophrenia
2004-000751-42Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of quetiapine in schizophrenia and bipolar I disorder, sponsored by AstraZeneca. Primary endpoint: Primary safety and tolerability. Started Feb 2006; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on 2004-000751-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000751-42.